MYL4 Inhibitors
MYL4 inhibitors belong to a distinctive chemical class characterized by their ability to modulate the activity of myosin light chain 4 (MYL4), a crucial protein involved in various cellular processes. MYL4 is a member of the myosin superfamily, serving as a regulatory subunit that plays a pivotal role in the regulation of smooth muscle contraction and cell motility. These inhibitors exert their effects by interacting with MYL4, thereby influencing the intricate balance of cellular signaling pathways associated with muscle function and cellular motility.
MYL4 inhibitors class is noteworthy, reflecting the intricate nature of MYL4 as a molecular target. Researchers have identified small molecules and compounds with distinct chemical scaffolds that demonstrate an affinity for MYL4, inhibiting its activity through various mechanisms. The development and exploration of MYL4 inhibitors contribute to a deeper understanding of the underlying molecular processes governing muscle contraction and cellular motility. Furthermore, elucidating the structural features and binding interactions of MYL4 inhibitors may pave the way for the design and synthesis of novel compounds with enhanced specificity and potency, opening new avenues for investigating the broader implications of MYL4 modulation in cellular physiology and beyond.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $72.00 $265.00 $495.00 $968.00 | ||
A potent inhibitor of myosin II ATPase activity, blebbistatin can inhibit the contractile activity of the myosin complex, which can indirectly affect the function of MYL4. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 is a selective inhibitor of myosin light chain kinase (MLCK), an enzyme that phosphorylates MYL4 leading to the activation of myosin ATPase and contraction. By inhibiting MLCK, ML-7 can indirectly inhibit MYL4. | ||||||
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $236.00 $987.00 | 5 | |
W-7 is a calmodulin antagonist. Since calmodulin mediates the activation of MLCK, the inhibition of calmodulin by W-7 can indirectly inhibit MLCK and hence MYL4. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated coiled-coil kinase), which can phosphorylate and activate MLCK. By inhibiting ROCK, Y-27632 can indirectly inhibit MLCK and hence MYL4. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a potent and selective inhibitor of protein kinase A (PKA), which can phosphorylate and activate MLCK. By inhibiting PKA, H-89 can indirectly inhibit MLCK and hence MYL4. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93 is a selective inhibitor of CaMKII (Calcium/calmodulin-dependent protein kinase II), which can phosphorylate and activate MLCK. By inhibiting CaMKII, KN-93 can indirectly inhibit MLCK and hence MYL4. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including MLCK. By inhibiting MLCK, staurosporine can indirectly inhibit MYL4. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a broad-spectrum protein kinase C (PKC) inhibitor, which can inhibit the activation of MLCK. By inhibiting PKC, Go6983 can indirectly inhibit MLCK and hence MYL4. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF-109203X is a potent and selective inhibitor of protein kinase C (PKC), which can inhibit the activation of MLCK. By inhibiting PKC, GF-109203X can indirectly inhibit MLCK and hence MYL4. | ||||||